SCHEMBL3192115

SCHEMBL3192115

COc1ccc(N(Cc2cccnc2)c2ccc(OC[C@H](O)CO)cc2)cc1OC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
ALDH1A1 P00352 4/20 0.46
PDE4A P27815 2/20 0.43
PDE4B Q07343 2/20 0.43
PDE4C Q08493 2/20 0.43
PDE4D Q08499 2/20 0.43
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
NPSR1 Q6W5P4 2/20 0.42
USP2 O75604 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
AGTR1 P30556 1/20 0.42
LMNA P02545 1/20 0.42
CYP1A2 P05177 1/20 0.42
FGFR1 P11362 1/20 0.42
FGFR2 P21802 1/20 0.42
FGFR4 P22455 1/20 0.42
FGFR3 P22607 1/20 0.42
KDR P35968 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3129573 0.90 PDE4A (0.51) MEN1KMT2AALDH1A1PDE4APDE4B
SCHEMBL3203614 0.87 ALDH1A1 (0.42) MEN1KMT2AALDH1A1PDE4APDE4B
SCHEMBL3202108 0.83 PDE4A (0.49) PDE4APDE4BPDE4CPDE4DTSHR
SCHEMBL7938249 0.81 PDE4A (0.51) ALDH1A1PDE4APDE4BPDE4CPDE4D
SCHEMBL3193748 0.79 GRM2 (0.43) PDE4BTSHRMAPK1FGFR1FGFR2
SCHEMBL1158682 0.78 PDE4A (0.48) ALDH1A1PDE4APDE4BPDE4CPDE4D
SCHEMBL1157867 0.77 GRM2 (0.52) ALDH1A1PDE4APDE4BPDE4CPDE4D
SCHEMBL4190538 0.77 ALDH1A1 (0.55) MEN1KMT2AALDH1A1PDE4APDE4B
SCHEMBL4193665 0.77 PDE4A (0.52) ALDH1A1PDE4APDE4BPDE4CPDE4D
SCHEMBL3129524 0.76 PDE4A (0.54) PDE4APDE4BPDE4CPDE4DFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US claimed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO claimed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS PDE4A, PDE4B, PDE3B MEN1 3385/4885KMT2A 1324/4885ALDH1A1 190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.